These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1116 related items for PubMed ID: 19034014

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
    Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
    Matsushita M, Yamazaki R, Ikeda H, Mori T, Sumimoto H, Fujita T, Okamoto S, Ikeda Y, Kawakami Y.
    Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
    Koh MB, Prentice HG, Lowdell MW.
    Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, Jedema I.
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
    Faber LM, van Luxemburg-Heijs SA, Rijnbeek M, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
    [Abstract] [Full Text] [Related]

  • 14. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 15. Minor histocompatibility antigens, defined by graft-vs.-host disease-derived cytotoxic T lymphocytes, show variable expression on human skin cells.
    De Bueger M, Bakker A, Van Rood JJ, Goulmy E.
    Eur J Immunol; 1991 Nov; 21(11):2839-44. PubMed ID: 1682155
    [Abstract] [Full Text] [Related]

  • 16. In vitro methotrexate as a practical approach to selective allodepletion.
    Sathe A, Ortega SB, Mundy DI, Collins RH, Karandikar NJ.
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):644-54. PubMed ID: 17531774
    [Abstract] [Full Text] [Related]

  • 17. Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
    Gaschet J, Mahé B, Milpied N, Devilder MC, Dréno B, Bignon JD, Davodeau F, Hallet MM, Bonneville M, Vié H.
    J Clin Invest; 1993 Jan; 91(1):12-20. PubMed ID: 8423212
    [Abstract] [Full Text] [Related]

  • 18. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
    Wehler TC, Nonn M, Brandt B, Britten CM, Gröne M, Todorova M, Link I, Khan SA, Meyer RG, Huber C, Hartwig UF, Herr W.
    Blood; 2007 Jan 01; 109(1):365-73. PubMed ID: 16931626
    [Abstract] [Full Text] [Related]

  • 19. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
    Montagna D, Daudt L, Locatelli F, Montini E, Turin I, Lisini D, Giorgiani G, Bernardo ME, Maccario R.
    Cancer Res; 2006 Jul 15; 66(14):7310-6. PubMed ID: 16849581
    [Abstract] [Full Text] [Related]

  • 20. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R.
    Biol Blood Marrow Transplant; 2004 Oct 15; 10(10):669-80. PubMed ID: 15389433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.